• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Lifevantage Corporation

    11/21/24 4:07:36 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LFVN alert in real time by email
    S-8 1 lfvns-8november2024.htm S-8 Document

    As filed with the Securities and Exchange Commission on November 21, 2024
    Registration No. 333-
    ________________________________________________________________________________
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     ________________________________________________________________________________
    FORM S-8
    REGISTRATION STATEMENT
    Under
    The Securities Act of 1933
    ________________________________________________________________________________

    LIFEVANTAGE CORPORATION
    (Exact name of registrant as specified in its charter)
    _______________________________________________________________________________

    Delaware
    (State or other jurisdiction of
    incorporation or organization)
     
    90-0224471
    (IRS Employer
    Identification No.)
    LifeVantage Corporation 2019 Employee Stock Purchase Plan
    (Full title of plan)
    ________________________________________________________________________________
    LifeVantage Corporation
    3300 Triumph Blvd., Suite 700
    Lehi, UT 84043
    (Name and address of agent for service)

    (801) 432-9000
    (Telephone number, including area code, of agent for service)
    ________________________________________________________________________________
     Copies to:
    Kirt W Shuldberg, Esq.
    Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
    3570 Carmel Mountain Rd., Suite 200
    San Diego, CA 92130
    (858) 436-8000
     ________________________________________________________________________________
    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated fileroAccelerated filero
    Non-accelerated filerýSmaller reporting companyý
    Emerging growth companyo
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o

    The registration statement shall become effective upon filing in accordance with Rule 462(a) under the Securities Act of 1933.



    PART I
    Information Required in the Section 10(a) Prospectus
    The information specified in this Part I is omitted from this Registration Statement on Form S-8, or the Registration Statement, in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended, or the Securities Act. In accordance with the rules and regulations of the Securities and Exchange Commission, or the SEC, and the instructions to Form S-8, such documents are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.
    PART II
     Information Required in the Registration Statement
    Item 3.   Incorporation of Documents by Reference
    The following documents and information previously filed by the Registrant with the SEC are hereby incorporated by reference in this registration statement:
    (1)the Registrant’s annual report on Form 10-K and any amendments thereto for the fiscal year ended June 30, 2024, filed on August 28, 2024;
    (2)the Registrant’s quarterly report on Form 10-Q and any amendments thereto for the fiscal quarter ended September 30, 2024, filed on October 29, 2024;

    (3)the Registrant’s current reports on Form 8-K filed on August 26, 2024, November 14, 2024 and November 19, 2024, only to the extent filed and not furnished;
    (4)all reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Securities Exchange of 1934 (the “Exchange Act”) since the end of the fiscal year covered by the Registrant’s latest annual report; and
    (5)the description of the Registrant’s common stock contained in the Registrant’s registration statement on Amendment No. 1 to Form 8-A filed under the Securities Act of 1933 on March 13, 2018, including any amendment or report filed for the purpose of updating such description.
    All other reports and documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, as amended, subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which de-registers all securities then remaining unsold shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents.  The Registrant is not, however, incorporating any documents or information that the Registrant is deemed to furnish and not file in accordance with SEC rules. Any statement contained in a document incorporated or deemed incorporated by reference in this Registration Statement will be deemed modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document that also is deemed incorporated by reference in this Registration Statement modifies or supersedes that statement.
    Item 4.   Description of Securities
    Not applicable.
    Item 5.   Interests of Named Experts and Counsel
    Not applicable.
    Item 6.   Indemnification of Directors and Officers
    Section 145 of the Delaware General Corporation Law authorizes a corporation’s board of directors to grant, and authorizes a court to award, indemnity to officers, directors and other corporate agents.
    As permitted by Section 102(b)(7) of the Delaware General Corporation Law, the Registrant’s amended and restated certificate of incorporation includes provisions that eliminate the personal liability of its directors and officers for monetary damages for a breach of their fiduciary duty as directors and officers.
    In addition, as permitted by Section 145 of the Delaware General Corporation Law, the Registrant’s amended and restated bylaws provide that:



    •The Registrant shall indemnify its directors and officers for serving the registrant in those capacities or for serving other business enterprises at the registrant’s request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful.
    •The Registrant may, in its discretion, indemnify employees and agents in those circumstances in which indemnification is not required by law.
    •The Registrant will be required to advance expenses, as incurred, to its directors and officers in connection with defending a proceeding, except that such director or officer shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.
    •The Registrant will not be obligated pursuant to the bylaws to indemnify a person with respect to proceedings initiated by that person, except with respect to proceedings authorized by the registrant’s board of directors. The rights conferred in the bylaws are not exclusive, and the registrant is authorized to enter into indemnification agreements with its directors, officers, employees and agents and to obtain insurance to indemnify such persons.
    •The Registrant may not retroactively amend the bylaw provisions to reduce its indemnification obligations to directors, officers, employees and agents.
    The Registrant has entered into separate indemnification agreements with each of its directors and executive officers that will provide the maximum indemnity allowed to directors and executive officers by Section 145 of the Delaware General Corporation Law and provide for certain additional procedural protections. The Registrant also maintains insurance to insure directors and officers against certain liabilities.
    These indemnification provisions and the indemnification agreements to be entered into between the registrant and its officers and directors may be sufficiently broad to permit indemnification of the registrant’s officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act.
    We have been advised that in the opinion of the SEC indemnification for liabilities arising under the Securities Act is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities is asserted by one of our directors, officers, or controlling persons in connection with the securities being registered, we will, unless in the opinion of our legal counsel the matter has been settled by controlling precedent, submit the question of whether such indemnification is against public policy to a court of appropriate jurisdiction. We will then be governed by the court’s decision.
    Item 7.   Exemption from Registration Claimed
    Not applicable.



    Item 8. Exhibits
    The following exhibits are incorporated herein by reference.
    No.Document DescriptionFiled Herewith or Incorporated by Reference From
    4.1
    Certificate of Incorporation
    Exhibit 3.1 to Form 8-K filed on March 13, 2018.
    4.2
    Amended and Restated Bylaws
    Exhibit 3.2 to Form 8-K filed on August 15, 2019.
    4.3
    Certificate of Designation of Series A Junior Participating Preferred Stock of the Registrant
    Exhibit 3.1 to Form 8-K filed on August 31, 2023.
    4.4
    Certificate of Elimination of Series A Junior Participating Preferred Stock of the Registrant, filed November 18, 2024
    Exhibit 3.1 to Form 8-K filed on November 19, 2024.
    4.5
    Form of Common Stock Certificate
    Exhibit 4.1 to Form 8-K filed on March 13, 2018.
    5.1
    Opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
    Filed herewith.
    23.1
    Consent of Deloitte & Touche, LLP, Independent Registered Public Accounting Firm
    Filed herewith.
    23.2Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLPContained in Exhibit 5.1.
    24.1Power of AttorneyContained on the signature page hereto.
    99.1LifeVantage Corporation 2019 Employee Stock Purchase Plan, as amended Annex B to the Registrant’s Proxy Statement on Schedule 14A, filed on September 20, 2024.
    107
    Filing Fee Table
    Filed herewith.

    Item 9.   Undertakings
     
    A.        The undersigned Registrant hereby undertakes:
     
    (1)       to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
     
    (i) to include any prospectus required by Section 10(a)(3) of the Securities Act,

    (ii) to reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement.  Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement, and
     
    (iii) to include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement; provided, however, that clauses A(1)(i) and A(1)(ii) above shall not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement;
     
    (2)     that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and
     
    (3)       to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the Registrant’s offering.



     
    B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
     
    C.       Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions or otherwise, the Registrant has been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable.  In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
     
     



    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lehi, Utah on this 21st day of November, 2024.
    LIFEVANTAGE CORPORATION
    By:/s/ Steven R. Fife
    Steven R. Fife
    President and Chief Executive Officer




    POWER OF ATTORNEY
    KNOW ALL PERSONS BY THESE PRESENTS that each person whose signature appears below constitutes and appoints Steven R. Fife and Carl Aure, and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this registration statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorney-in-fact and agents or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.
    IN WITNESS WHEREOF, each of the undersigned has executed this Power of Attorney as of the date indicated.
    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
    SignatureTitleDate
    /s/ Steven R. Fife
    President and Chief Executive Officer (Principal Executive Officer)
    November 21, 2024
    Steven R. Fife
    /s/ Carl Aure
    Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
    November 21, 2024
    Carl Aure
    /s/ Raymond GreerDirector, Chairman of the BoardNovember 21, 2024
    Raymond B. Greer
    /s/ Rajendran AnbalaganDirectorNovember 21, 2024
    Rajendran Anbalagan
    /s/ Michael A. BeindorffDirectorNovember 21, 2024
    Michael A. Beindorff
    /s/ Dayton JuddDirectorNovember 21, 2024
    Dayton Judd
    /s/ Cynthia LathamDirectorNovember 21, 2024
    Cynthia Latham
    /s/ Darwin LewisDirectorNovember 21, 2024
    Darwin Lewis
    /s/ Garry MauroDirectorNovember 21, 2024
    Garry Mauro


    Get the next $LFVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LFVN

    DatePrice TargetRatingAnalyst
    1/14/2025$35.00Buy
    Craig Hallum
    12/19/2024$26.00Buy
    Lake Street
    More analyst ratings

    $LFVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mauro Garry Paul bought $26,338 worth of shares (2,150 units at $12.25), increasing direct ownership by 0.70% to 86,087 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      5/13/25 4:11:14 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Sales Officer Cunningham Kristen covered exercise/tax liability with 3,659 shares, decreasing direct ownership by 3% to 104,388 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      4/30/25 4:23:59 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Fife Steven R covered exercise/tax liability with 21,089 shares, decreasing direct ownership by 3% to 632,371 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      4/3/25 6:06:36 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Leadership Updates

    Live Leadership Updates

    See more
    • LifeVantage Welcomes Todd Thompson as Chief Information and Innovation Officer

      SALT LAKE CITY, Jan. 16, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, is proud to announce the addition of Todd Thompson as Chief Information and Innovation Officer. Todd brings decades of experience driving transformative technology solutions and business growth for prominent global organizations. "We are thrilled to welcome Todd to the LifeVantage team," said Steve Fife, President and CEO of LifeVantage. "Todd's exceptional track record in technology leadership and his forward-thinking approach will be pivotal as we continue along our growth path

      1/16/25 8:00:00 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage Welcomes Rajendran Anbalagan to the Board of Directors; Thanks Erin Brockovich for Her Years of Service

      SALT LAKE CITY, Aug. 26, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, announced the appointment of Rajendran Anbalagan to the Company's Board of Directors effective today. The appointment comes after the Board conducted a comprehensive search to identify a candidate with transformational digital skills and identified Mr. Anbalagan as an exceptional choice. "We are very excited to welcome Rajendran Anbalagan to the LifeVantage Board," said Ray Greer, Chairman. "Raj brings extensive technology experience along with a deep understanding of how to lever

      8/26/24 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage To Host "LifeVantage Open House" Virtual Calls on July 23 and 24

      SALT LAKE CITY, July 22, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, will host Open House calls on July 23 and 24, for anyone wanting to learn more about LifeVantage, its activating products, and the Company's industry-leading compensation plan designed to meet modern sharers by supporting both product sellers and team builders. The Open House call on the 23rd will feature a Q&A with LifeVantage President and CEO, Steve Fife, Chief Sales Officer, Kristen Cunningham, and Regional Vice President of Sales, Jake Hines. The discussion will include the e

      7/22/24 6:27:51 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Lifevantage Corporation

      SC 13D/A - Lifevantage Corp (0000849146) (Subject)

      7/31/24 8:07:09 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

      SC 13D/A - Lifevantage Corp (0000849146) (Subject)

      2/15/24 4:29:36 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

      SC 13D/A - Lifevantage Corp (0000849146) (Subject)

      2/15/24 4:27:16 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Financials

    Live finance-specific insights

    See more
    • LifeVantage Declares Quarterly Dividend

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid June 13, 2025 to all stockholders of record at the close of business on May 30, 2025. This represents an increase in the dividend amount by 12.5% over the previous quarter. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally o

      5/6/25 4:06:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2025

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2025. Third Quarter Fiscal 2025 Summary*: Revenue was $58.4 million, an increase of 21.1% from the prior year period. Excluding the negative impact of foreign currency fluctuations, third quarter revenue increased approximately 22.1%;Revenue in the Americas increased 29.5%, and revenue in Asia/Pacific & Europe decreased 7.2%. Excluding the negative impact of foreign currency fluctuations, third quarter

      5/6/25 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage to Announce Third Quarter Fiscal Year 2025 Results on May 6, 2025

      SALT LAKE CITY, April 22, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its third quarter ended March 31, 2025, after the stock market closes on Tuesday, May 6, 2025. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours after th

      4/22/25 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    SEC Filings

    See more
    • Lifevantage Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Lifevantage Corp (0000849146) (Filer)

      5/6/25 4:06:34 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Lifevantage Corporation

      10-Q - Lifevantage Corp (0000849146) (Filer)

      5/6/25 4:05:28 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Lifevantage Corporation

      10-Q - Lifevantage Corp (0000849146) (Filer)

      2/5/25 4:05:56 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LifeVantage Declares Quarterly Dividend

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid June 13, 2025 to all stockholders of record at the close of business on May 30, 2025. This represents an increase in the dividend amount by 12.5% over the previous quarter. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally o

      5/6/25 4:06:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2025

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2025. Third Quarter Fiscal 2025 Summary*: Revenue was $58.4 million, an increase of 21.1% from the prior year period. Excluding the negative impact of foreign currency fluctuations, third quarter revenue increased approximately 22.1%;Revenue in the Americas increased 29.5%, and revenue in Asia/Pacific & Europe decreased 7.2%. Excluding the negative impact of foreign currency fluctuations, third quarter

      5/6/25 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Global Convention 2025 Empowers Consultants to 'Go Further' with Exclusive Trainings, Product Announcements, and New Incentives to Drive Growth

      SALT LAKE CITY, April 28, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the successful conclusion of their annual Global Convention, held April 24-26, 2025, in Salt Lake City, Utah. Thousands of independent LifeVantage Consultants from around the world gathered at the Salt Palace Convention Center to participate in the multi-day event. Attendees heard from a variety of LifeVantage executives and speakers on key business updates, exciting product announcements, exclusive business and compensation plan trainings, and initiatives designed

      4/28/25 8:00:00 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mauro Garry Paul bought $26,338 worth of shares (2,150 units at $12.25), increasing direct ownership by 0.70% to 86,087 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      5/13/25 4:11:14 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lewis Darwin bought $3,632 worth of shares (227 units at $16.00), increasing direct ownership by 0.20% to 116,388 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      12/17/24 5:00:17 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lewis Darwin bought $3,618 worth of shares (351 units at $10.31), increasing direct ownership by 0.33% to 108,342 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      9/17/24 6:20:09 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Lifevantage with a new price target

      Craig Hallum initiated coverage of Lifevantage with a rating of Buy and set a new price target of $35.00

      1/14/25 8:36:52 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Street initiated coverage on Lifevantage with a new price target

      Lake Street initiated coverage of Lifevantage with a rating of Buy and set a new price target of $26.00

      12/19/24 8:39:43 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care